ADIL On Track, PGNX Slumps On Phase III Study Failure, VNDA On Watch

Today's Daily Dose brings you news about disappointing results of Progenics Pharma's 1404, an imaging compound targeting prostate specific membrane antigen,trial; stock offerings of Galapagos and Xenon Pharma and Hetlioz's edge over Zopiclone in driving impairment.

from RTT - Biotech https://ift.tt/2N6hr3r
via IFTTT